Pharmaceuticals Japan

Japan Hyperuricemia Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Japan Hyperuricemia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $165.9 Mn Placeholder estimate
Estimate 2025 $178.6 Mn 6.5% of the global market
Projected 2034 $348.3 Mn 95% Adds $169.6 Mn over 9 forecast years
CAGR 2025–2034 7.7% Faster than 41% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 6.5% of the global market.
  • In APAC, the largest is China at $206.3 Mn.
  • Fastest growing: India at 10.2% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$169.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Hyperuricemia Drugs Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $165.9 Mn — —
2025 (base) $178.6 Mn +$12.8 Mn —
2026 (forecast) $192.4 Mn +$13.8 Mn +7.7%
2027 (forecast) $207.2 Mn +$14.8 Mn +16%
2028 (forecast) $223.2 Mn +$16.0 Mn +24.9%
2029 (forecast) $240.3 Mn +$17.2 Mn +34.5%
2030 (forecast) $258.8 Mn +$18.5 Mn +44.9%
2031 (forecast) $278.8 Mn +$19.9 Mn +56.1%
2032 (forecast) $300.2 Mn +$21.5 Mn +68.1%
2033 (forecast) $323.4 Mn +$23.1 Mn +81%
2034 (forecast) $348.3 Mn +$24.9 Mn +95%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Japan Hyperuricemia Drugs Market Analysis at a glance
Market size, 2025$178.6 Mn placeholder estimate
Forecast, 2034$348.3 Mn placeholder estimate
Growth (CAGR), 2025–20347.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, indication and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Amgen Inc., Teijin Pharma, Fuji Yakuhin, Arthrosi Therapeutics (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials2 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Hyperuricemia Drugs Market Analysis Executive Summary

Hyperuricemia drugs lower high uric acid in the blood, which can cause gout and kidney stones and is linked to heart and kidney disease.

Key segments of the hyperuricemia Drugs market include drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors and Recombinant Uricase) and indication (Gout, Chronic Kidney Disease and Tumor Lysis Syndrome).

Bar chart: Japan Hyperuricemia Drugs market size, 2024–2034, placeholder estimates. $165.9 Mn in 2024, $178.6 Mn in 2025 and $348.3 Mn in 2034, 7.7% CAGR.
Japan Hyperuricemia Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Hyperuricemia Drugs Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the hyperuricemia Drugs market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the hyperuricemia Drugs market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Hyperuricemia Drugs Market in Japan

The hyperuricemia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Hyperuricemia Drugs Market in Japan

Hyperuricemia Drugs in Japan: rules, payment and research

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 2 studies on Hyperuricemia Drugs that are recruiting, active or about to start in Japan.⁠[3]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for hyperuricemia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Hyperuricemia Drugs right now, from free public sources.

Clinical trials

2 active trials in Japan

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Crystalys Therapeutics 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Shanton Pharma 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Hyperuricemia Drugs in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Hyperuricemia Drugs market in Japan?
Placeholder estimate: about $178.6 Mn in 2025, rising to about $348.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Hyperuricemia Drugs market in Japan growing?
Placeholder estimate: about 7.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Hyperuricemia Drugs market report cover?
The report splits the market by drug class (Xanthine Oxidase Inhibitors, URAT1 Inhibitors, Recombinant Uricase), indication (Gout, Chronic Kidney Disease, Tumor Lysis Syndrome) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Hyperuricemia Drugs market?
Key players include Takeda Pharmaceutical Company Ltd, Amgen Inc., Teijin Pharma, Fuji Yakuhin and Arthrosi Therapeutics.
What is driving the Hyperuricemia Drugs market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the hyperuricemia Drugs market.
Who regulates Hyperuricemia Drugs in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on Hyperuricemia Drugs are running in Japan?
2 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 12 Nov 2026.
How much research is published on Hyperuricemia Drugs?
PubMed lists 2,548 papers on Hyperuricemia Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Japan

See all

Related on kidney health

See the topic